Abstract:Objective: The dynamic adaptive immune responses elicited by the inactivated virus vaccine CoronaVac remain elusive. Methods: In a prospective cohort of 100 healthcare professionals naive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received two doses of CoronaVac, we analysed SARS-CoV-2-specific humoral and cellular responses at four different timepoints, including before vaccination (T1), 2 weeks after the first dose (T2), 2 weeks after the booster dose (T3), and 8-10 weeks after the booster dose (T4). SARS-CoV-2-specific antibodies, serum neutralizing activities, peripheral B cells, CD4(+) and CD8(+) T cells and their memory subsets were simultaneously measured in this cohort. Results: SARS-CoV-2 spike-specific IgG responses reached a peak (geometric mean titre (GMT) 54827, 30969-97065) after two doses and rapidly declined (GMT 502, 212-1190) at T4, whereas suboptimal IgA responses were detected (GMT 5, 2-9). Spike-specific circulating B cells (0.60%, 0.46-0.73% of total B cells) and memory B cells (1.18%, 0.92-1.44% of total memory B cells) were effectively induced at T3 and sustained over time (0.33%, 0.23-0.43%; 0.87%, 0.05-1.67%, respectively). SARS-CoV-2-specific circulating CD4(+) T cells (0.57%, 0.47-0.66%) and CD8(+) T cells (1.29%, 1.04-1.54%) were detected at T3. At T4, 0.78% (0.43-1.20%) of memory CD4+ T cells and 0.68% (0.29-1.30%) of memory CD8(+) T cells were identified as SARS-CoV-2-specific, while 0.62% (0.51-0.75%) of CD4(+) T cells and 0.47% (0.38-0.58%) of CD8(+) T cells were SARS-CoV-2-specific terminally differentiated effector memory cells. Furthermore, age and interval between doses affected the magnitude of CoronaVac-induced immune responses. SARS-CoV-2 memory CD4(+) T cells were strongly associated with both receptor binding domain (RBD)-specific memory B cells (r 0.87, p <0.0001) and SARS-CoV-2-specific memory CD8(+) T cells (r 0.48, p <0.0001). Conclusions: CoronaVac induced robust circulating and memory B cell and T cell responses. Our study offers new insight into the underlying immunobiology of inactivated virus vaccines in humans and may have implications for vaccine strategies in the future. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Impaired Humoral Immunity Identified in Inactivated SARS-CoV-2 Vaccine Recipients without Anti-Spike RBD Antibodies

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

Pre‐existing Immunity to SARS‐CoV‐2 Associates with Strong T Cell Responses Induced by Inactivated COVID‐19 Vaccines

SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination

SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine

SARS-CoV-2 spike-specific T FH cells exhibit unique responses in infected and vaccinated individuals

Non-spike and Spike-Specific Memory T Cell Responses after the Third Dose of Inactivated COVID-19 Vaccine

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

Protective Antigenic Epitopes Revealed by Immunosignatures after Three Doses of Inactivated SARS-CoV-2 Vaccine

Potent and Persistent Antibody Responses Against the Receptor-Binding Domain of SARS-CoV Spike Protein in Recovered Patients

Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy

Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein

Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform

Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study

Dynamic SARS-CoV-2-specific B-cell and T-cell Responses Following Immunization with an Inactivated COVID-19 Vaccine

Protective Humoral and Cellular Immune Responses to SARS-CoV-2 Persist Up to 1 Year after Recovery.

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing

Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals

Broad and Durable Antibody Response after Vaccination with Inactivated SARS-CoV-2 in Individuals with a History of 2003 SARS-CoV Infection.

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells